Possible long-term consequences for patients with diabetes forced to switch to alternative medications during the semaglutide shortage include the risk of losing ground in glycemic control, having uncontrolled diabetes with associated symptoms, and other adverse events.
The potential long-term consequences for patients with diabetes forced to switch to alternative medications during the semaglutide shortage include the risk of losing ground in glycemic control, having uncontrolled diabetes with associated symptoms, and other adverse events, according to Ian Neeland, MD. Neeland is the director of cardiovascular prevention and co-director of the Center for Integrated and Novel Approaches in Vascular-Metabolic Disease at the University Hospitals Harrington Heart & Vascular Institute, as well as associate professor of medicine at Case Western Reserve University School of Medicine.
Transcript
Can you elaborate on the potential long-term consequences for patients with diabetes who are forced to switch to alternative medications amid the shortage?
Switching for these medications, as I mentioned, requires starting at lower doses and escalating those doses over time. So, you may lose ground when you're switching from one to the other in terms of your glycemic control, and you can have poor control for that during that period of time, whereas previously things were stable. And obviously, when you create an unstable situation of diabetes control, that can lead to symptoms or adverse consequences that you would see with uncontrolled diabetes, so that is certainly a concern over that. There are definitely plenty of options for diabetes management, though, so if one drug has to be stopped for a while, there are others that can be substituted, although many of the others don't have the same cardiovascular or kidney benefits as things like the GLP-1 receptor agonists or the GIP receptor agonist.
It's important to try to maintain glycemic control in the context of guideline-based, evidence-based therapies that have benefits for cardiometabolic kidney in general, as opposed to something like a sulfonylurea instead, which really can control blood sugar but has no other positive cardiovascular benefit. I think that creates an issue, and switching from one drug to the other, you can create adverse issues like side effects that can occur. Often when patients will stop a medication because of a drug shortage, one of these injectable medications, what they do is they start back at the dose they were previously on, and that's usually a bad idea because the side effects can be very severe. For example, I had a patient who was on 2 milligrams of semaglutide and had to stop for whatever reason for several weeks, and they started again, but they start at the 2 milligram dose and they got pretty ill. That's an issue and a concern which obviously can be mitigated with education, counseling, appropriate information for the patients, but anytime you're kind of switching things up and moving things around, things get lost in translation and you may have issues, controlling blood sugar and controlling risk factors.
ATS 2024 Data Support Triple Therapy FF/UMEC/VI as Preferred Option for COPD
May 21st 2024New data reveal that starting furoate/umeclidinium/vilanterol (FF/UMEC/VI) without delay not only significantly reduces exacerbations and health care costs but also enhances adherence and persistence for patients with chronic obstructive pulmonary disease (COPD) compared with other therapies.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Unique Case: HCC With No Cirrhosis—and “Hidden” CLL/SLL
May 21st 2024A 77-year-old man had no risk factors for hepatocellular carcinoma (HCC), but he was nonetheless found to have it. Along the way, he was also diagnosed with previously undetected chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Exploring Critical Advances in ARDS, Asthma, Lung Cancer, Health Equity at ATS 2024
May 20th 2024During a session at the American Thoracic Society (ATS) 2024 International Conference, experts presented the most impactful data from the last year on acute respiratory distress syndrome (ARDS), childhood asthma, health equity, and lung cancer.
Read More
Patients With COPD, PRISm at Increased All-Cause, Cause-Specific Mortality Risk
May 20th 2024Patients with chronic obstructive pulmonary disease (COPD) and/or preserved ratio impaired spirometry (PRISm) have an increased risk of all-cause and cause-specific mortality, highlighting the need for better understanding of these conditions through increased spirometry data collection.
Read More